Solutions for Change

Adamis Pharmaceuticals is a clinical stage neuro-biotechnology company committed to patients. Our commercial and development products aim to address areas of significant unmet medical need.

ZIMHI technology video

ZIMHI Technology – watch our video that explains how it works

Scientist working in a lab

About Us

Adamis Pharmaceuticals is a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease.

Commercially approved products:

  • ZIMHI® (naloxone) Injection is FDA approved for opioid overdose emergency rescue
  • SYMJEPI® (epinephrine) Injection is FDA approved for use in the emergency treatment of acute allergic reactions, including anaphylaxis.

Learn More - Products

The following molecules are in development:.

  • DPI-125 for the treatment of Opioid Use Disorder (OUD).
  • DPI-221 for the treatment of benign prostatic hyperplasia (BPH).
  • DPI-289 for the treatment of Parkinson’s disease.
Learn More - Pipeline

Sign Up For Adamis Pharmaceuticals Email Alerts

Choose Your Preferences

Adamis Pharmaceuticals is a clinical stage neuro-biotechnology company focused on the development and commercialization of potential blockbuster products for the treatment of a variety of neuro-based disorders with significant unmet medical needs.

Linkedin Twitter

COMPANY

PRODUCTS

PIPELINE

INVESTORS & MEDIA

CONNECT

Adamis Pharmaceuticals logo

ADAMIS Announces Merger With DMK Pharmaceuticals

What is DMK?
Private, clinical-stage, neuro-biotech company
  • Focused on developing potential blockbuster products for underserved patients.
  • Product candidates selected and developed from proprietary library of approximately 750 small molecule neuropeptide analogues with broad utility.

Developing multiple first-in-class products targeting large unmet needs
  • Addiction
  • Acute and chronic pain
  • Parkinson’s disease
  • Bladder control
  • Other neuro-based diseases

Want to learn more?

Read our press release go to our Investor Relations page or visit https://dmkpharma.com/

Check this page for the most recent updates regarding the merger process.